Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASCO 2016 | Preliminary results of the AIM trial of ibrutinib and venetoclax in mantle cell lymphoma

Constantine Tam • 3 Jun 2016

ASCO 2016

Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Venetoclax

AIM

Constantine Tam, MBBS, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the preliminary results of the Phase II AIM study of ibrutinib and venetoclax (ABT-199) in relapsed/refractory mantle cell lymphoma (NCT02471391) presented at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. Dr Tam outlines how of the eight patients who have completed a four month course, five are in complete remission (CR), two patients in partial remission, and one patient did not respond. Dr Tam further discusses the promise of this drug combination and the associated toxicities.

ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL

Constantine Tam • 11 Dec 2023

The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies

Constantine Tam • 11 Dec 2023

SYMPATICO: Primary analysis results of ibrutinib plus venetoclax for patients with R/R MCL

Constantine Tam • 11 Dec 2023

Sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve CLL/SLL

Constantine Tam • 11 Dec 2023

Related Videos

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024

The role of CAR-T therapy for lymphoma in 2024: expert session highlights

Sridhar Chaganti • 16 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024

Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni • 15 Apr 2024